New CAR T-Cell therapy shows promise for Tough-to-Treat myeloma
NCT ID NCT04322292
First seen Feb 26, 2026 · Last updated May 01, 2026 · Updated 11 times
Summary
This early-phase study tested a new treatment called C-CAR088 in 9 people with multiple myeloma that had returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main goal was to check safety and see how well the therapy works in controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
InstituteHBDH
Tianjin, 300000, China
Conditions
Explore the condition pages connected to this study.